Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

Cullen, M H; Stenning, S P; Parkinson, M C; Fossa, S D; Kaye, S B; Horwich, A H; Harland, S J; Williams, M V; Jakes, R

Cullen, M H; Stenning, S P; Parkinson, M C; Fossa, S D; Kaye, S B; Horwich, A H; Harland, S J; Williams, M V; Jakes, R.

Affiliation

Cullen MH; Birmingham Oncology Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom.

J Clin Oncol ; 14(4): 1106-13, 1996 Apr.

Article in En | MEDLINE | ID: mdl-8648364

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Dysgerminoma/drug therapy; Testicular Neoplasms/drug therapy; Adult; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bleomycin/administration & dosage; Chemotherapy, Adjuvant; Cisplatin/administration & dosage; Drug Administration Schedule; Dysgerminoma/pathology; Dysgerminoma/surgery; Etoposide/administration & dosage; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prognosis; Risk Factors; Testicular Neoplasms/pathology; Testicular Neoplasms/surgery; Time Factors; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Testicular Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Dysgerminoma Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Adult / Humans / Male Language: En Journal: J Clin Oncol Year: 1996 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links